Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Morgenstern

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
Pediatric Blood & Cancer|February 7, 2025
Comment on: Incidence of Adrenal Insufficiency in Patients with High-Risk Neuroblastoma: A Single-Institution AnalysisDaniel A Morgenstern, Sarah Cohen-Gogo, Denise Connolly, et al.
Molecular and Cellular Neurosciences|May 4, 2005
Two separate metalloproteinase activities are responsible for the shedding and processing of the NG2 proteoglycan in vitroRichard A Asher, Daniel A Morgenstern, Francesca Properzi, et al.
Molecular and Cellular Neurosciences|December 11, 2003
Expression and glycanation of the NG2 proteoglycan in developing, adult, and damaged peripheral nerveDaniel A Morgenstern, Richard A Asher, Murali Naidu, et al.
PET Clinics|May 31, 2021
Theranostics in NeuroblastomaMargarida Simao Rafael, Sarah Cohen-Gogo, Meredith S Irwin, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|March 16, 2002
Versican is upregulated in CNS injury and is a product of oligodendrocyte lineage cellsRichard A Asher, Daniel A Morgenstern, Morven C Shearer, et al.
Pediatric Blood & Cancer|February 11, 2023
Pain mitigation and management strategies for anti-GD2 infusions: An expert consensusKarsten Nysom, Andrea Gomez Morad, Margarida Simão Rafael, et al.
Cancer Reports (Hoboken, N.J.)|May 17, 2022
Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse eventsJaume Mora, Godfrey C Chan, Daniel A Morgenstern, et al.
Paediatrics & Child Health|July 24, 2023
Precision oncology for children: A primer for paediatriciansSarah Cohen-Gogo, Avram E Denburg, Anita Villani, et al.
Journal of Clinical Medicine|November 27, 2024
Characterisation of Paediatric Neuroblastic Tumours by Quantitative Structural and Diffusion-Weighted MRIDomenica Tambasco, Margalit Zlotnik, Sayali Joshi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 18, 2012
Human γδ T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cellsNourredine Himoudi, Daniel A Morgenstern, Mengyong Yan, et al.
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
Pediatric Blood & Cancer|February 7, 2025
Comment on: Incidence of Adrenal Insufficiency in Patients with High-Risk Neuroblastoma: A Single-Institution AnalysisDaniel A Morgenstern, Sarah Cohen-Gogo, Denise Connolly, et al.
Molecular and Cellular Neurosciences|May 4, 2005
Two separate metalloproteinase activities are responsible for the shedding and processing of the NG2 proteoglycan in vitroRichard A Asher, Daniel A Morgenstern, Francesca Properzi, et al.
Molecular and Cellular Neurosciences|December 11, 2003
Expression and glycanation of the NG2 proteoglycan in developing, adult, and damaged peripheral nerveDaniel A Morgenstern, Richard A Asher, Murali Naidu, et al.
PET Clinics|May 31, 2021
Theranostics in NeuroblastomaMargarida Simao Rafael, Sarah Cohen-Gogo, Meredith S Irwin, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|March 16, 2002
Versican is upregulated in CNS injury and is a product of oligodendrocyte lineage cellsRichard A Asher, Daniel A Morgenstern, Morven C Shearer, et al.
Pediatric Blood & Cancer|February 11, 2023
Pain mitigation and management strategies for anti-GD2 infusions: An expert consensusKarsten Nysom, Andrea Gomez Morad, Margarida Simão Rafael, et al.
Cancer Reports (Hoboken, N.J.)|May 17, 2022
Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse eventsJaume Mora, Godfrey C Chan, Daniel A Morgenstern, et al.
Paediatrics & Child Health|July 24, 2023
Precision oncology for children: A primer for paediatriciansSarah Cohen-Gogo, Avram E Denburg, Anita Villani, et al.
Journal of Clinical Medicine|November 27, 2024
Characterisation of Paediatric Neuroblastic Tumours by Quantitative Structural and Diffusion-Weighted MRIDomenica Tambasco, Margalit Zlotnik, Sayali Joshi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 18, 2012
Human γδ T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cellsNourredine Himoudi, Daniel A Morgenstern, Mengyong Yan, et al.
Pageof 7